NEW BRUNSWICK, N.J., May 27 (UPI) -- New Jersey's Johnson & Johnson says it has 17 new medicines in advanced stages of clinical testing or awaiting regulatory approval.
That's a big improvement of the last such report, in 2001, when the company said it had only two drugs at the same stage of development, the Wall Street Journal reported Friday.
The drugmaker attributes its improved output to improved research productivity, a slew of acquisitions and aggressive licensing. The experimental drugs treat illnesses that include the AIDS virus and various cancers.
Other prospects include dapoxetine, a pill for premature ejaculation; paliperidone, an antipsychotic related to Risperdal; and Yondelis, for soft-tissue sarcoma.
|Additional Business News Stories|
WASHINGTON, May 21 (UPI) --A member of Congress who led an investigation into the BP oil spill in 2010 expressed outrage that a judge threw out a charge against a former BP executive.
MUSCAT, Oman, May 21 (UPI) --The Persian Gulf sultanate of Oman is set to buy a $2.1 billion missile system built by the U.S. Raytheon Co. as part of a U.S. drive to install a coordinated air-defense system linking the region's Arab monarchies to counter Iran.